Influence of antidepressant drugs on chlorpromazine metabolism in human liver - An in vitro study

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1062-1069

  Wójcikowski, Jacek ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chlorpromazine metabolism; Cytochrome P450; Fluvoxamine; Human liver microsomes; Imipramine; Inhibition

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; FLUVOXAMINE; IMIPRAMINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; SULFOXIDATION;

EID: 79551494499     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70368-6     Document Type: Article

References (36)

1. Ball SE, Ahern D, Scatina J, Kao J: Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol, 1997, 43, 619-626.
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Kuss HJ, Laux G et al.: The AGNP TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry, 2004, 37, 243-265.
3. Belpaire FM, Wijanant P, Temmerman A, Rasmussen BB, Brøsen K: The oxidative metabolism of metoprolol in human liver microsomes: inhibition by selective serotonin reuptake inhibitors. Eur J Clin Pharmacol, 1998, 54, 261-264.
4. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol, 1993, 45, 1211-1214. (Pubitemid 23098317)
5. Bylund DB: Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors. J Pharmacol Exp Ther, 1981, 217, 81-86.
6. Daniel W: Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats. Pol J Pharmacol Pharm, 1991, 43, 197-202.
7. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
8. Daniel W, Melzacka M: The effect of neuroleptics on imipramine demethylation in rat liver microsomes and imipramine and desipramine level in the brain. Biochem Pharmacol, 1986, 35, 3249-3253.
9. Daniel WA, Syrek M, Haduch A, Wójcikowski J: Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. J Pharm Pharmacol, 2000, 52, 1473-1481.
10. Daniel WA, Syrek M, Haduch A, Wójcikowski J: Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. Br J Pharmacol, 2000, 131, 287-295.
11. Daniel WA, Syrek M, Haduch A, Wójcikowski J: The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. J Pharm Pharmacol, 2001, 53, 449-461. (Pubitemid 32396535)
12. Daniel WA, Syrek M, Haduch A, Wójcikowski J: The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp Toxicol Pathol, 1999, 51, 309-314.
13. Daniel WA, Syrek M, Wójcikowski J: The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in rat. Eur Neuropsychopharmacol, 1999, 9, 337-344.
14. Daniel WA, Wójcikowski J: Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol, 1997, 80, 62-68.
15. i. Biochem J, 1972, 129, 197-202.
16. Haduch A, Wójcikowski J, Daniel WA: The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol, 2006, 16, 178-186.
17. 2-adrenoceptor binding. Eur J Pharmacol, 1986, 125, 373-381.
18. Heiman EM: Cardiac toxicity with thioridazine-tricyclic antidepressant combination. J Nerv Ment Dis, 1977, 165, 139-145.
19. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RWet al.: Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther, 1998, 64, 257-268.
20. Keck P, McElroy SL, Strakowski SM, West SA: Pharmacologic treatment of schizoaffective disorder. Psychopharmacology, 1994, 114, 529-538.
21. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P et al.: Major pathway of imipramine metabolism is characterized by cytochrome P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol, 1993, 43, 827-832. (Pubitemid 23146284)
22. Liu X, De Haan S: Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev, 2009, CD007778.
23. Loga S, Curry S, Lader M: Interaction of chlorpromazine and nortryptyline in patients with schizophrenia. Clin Pharmacokinet, 1981, 6, 454-462.
24. Nelson JC: Combined treatment strategies in psychiatry. J Clin Psychiatry, 1993, 54, Suppl 9, 42-49.
25. Nelson JC, Jatlow PI: Neuroleptic effect on desipramine steady-state plasma concentration. Am J Psychiatry, 137, 1232-1234.
26. Palmer GC, Blosser JC, McCreddy SA, Barrantes A, Manian AA: Correlation of activity of chlorpromazine and respective hydroxy, dimethoxy and sulphoxide analogues on dopamine, muscarinic, histamine and calmoduline sites of action. Xenobiotica, 1988, 18, 277-289.
27. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol, 1995, 39, 151-159.
28. Rasmussen BB, Nielsen TL, Brøsen K: Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol, 1998, 54, 735-740.
29. Silver H, Nassar A: Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol Psychiatry, 1992, 31, 698-704.
30. Syrek M, Wójcikowski J, Daniel WA: Promazine pharmacokinetics during concurrent treatment with tricyclic antidepressants. Pol J Pharmacol, 1997, 49, 453-462.
31. Vandel B, Vandel S, Allers G, Bechtel P, Volmat R: Interaction between amitriptyline and phenothiazine in man: Effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology, 1979, 65, 187-190. (Pubitemid 10226370)
32. Wójcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver - A comparison with other phenothiazines. Biochem Pharmacol, 2010, 80, 1252-1259.
33. Wójcikowski J, Daniel WA: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol, 2000, 52, 449-457. (Pubitemid 32045908)
34. Wójcikowski J, Daniel WA: Perazine at therapeutic drug concentration inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism - an in vitro study. Pharmacol Rep, 2009, 61, 851-858.
35. Wójcikowski J, Daniel WA: Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. Pol J Pharmacol, 2002, 54, 647-654.
36. Yoshii K, Kobayashi K, Tsumuji M, Tani M S, Shimada N, Chiba K: Identification of human cytochrome P450 isoform involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci, 2000, 67, 175-184.